SVB Securities analyst David Risinger maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $48.00. The company’s shares closed yesterday at $43.97.
According to TipRanks, Risinger is a 4-star analyst with an average return of 5.3% and a 55.20% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Roivant Sciences.
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $50.46, implying a 14.76% upside from current levels. In a report released yesterday, Atlantic Equities also maintained a Hold rating on the stock with a $46.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $54.46 and a one-year low of $40.72. Currently, Pfizer has an average volume of 21.86M.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year. Most recently, in December 2022, Albert Bourla, the Chairman & CEO of PFE bought 431,131.00 shares for a total of $11,944,560.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Pfizer Inc Reported Earnings. Did it Beat Estimates?
- Pfizer CEO: Our best days are still ahead of us
- Pfizer Issues Weak 2023 Guidance; Expects Significant Sales Drop
- Pfizer says incremental share repurchases ‘not high priority at this point’
- Pfizer CFO says increasing investments behind launch products and pipeline